Showing results (391-400 of 453) with videos related to
Sort By:
Pageof 46
Brain : a Journal of Neurology|November 15, 2025
The genetic landscape of frontotemporal lobar degeneration: investigation of a diagnostic cohort of 2747 probandsGuillaume Cogan, Marion Houot, Julie Bogoin, et al.Leukemia & Lymphoma|December 6, 2021
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphomaAhmad S Halwani, Carlos Panizo, Iris Isufi, et al.Hematological Oncology|July 12, 2025
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell LymphomaJuliette Penichoux, Pierre Decazes, Cédric Rossi, et al.Hematological Oncology|July 5, 2022
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network studyNadia Younan, Carole Soussain, Sylvain Choquet, et al.British Journal of Haematology|May 15, 2024
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registryB Ferment, J Lambert, D Caillot, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Javier Munoz, Andre Goy, et al.Neurobiology of Disease|April 1, 2023
Plasma lysosphingolipids in GRN-related diseases: Monitoring lysosomal dysfunction to track disease progressionWalid Khrouf, Dario Saracino, Benoit Rucheton, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trialGandhi Damaj, Rémy Gressin, Krimo Bouabdallah, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 20, 2019
Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with NivolumabAiping Chen, Fatima-Zohra Mokrane, Lawrence H Schwartz, et al.Blood Advances|January 9, 2026
Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphomaEmilie Charton, Amélie Anota, Emmannuel Bachy, et al.Pageof 46